VGLL3 antibody (FITC)
Quick Overview for VGLL3 antibody (FITC) (ABIN1401326)
Target
See all VGLL3 AntibodiesReactivity
Host
Clonality
Conjugate
Application
-
-
Cross-Reactivity
- Human, Mouse, Rat
-
Purification
- Purified by Protein A.
-
Immunogen
- KLH conjugated synthetic peptide derived from human VGLL3
-
Isotype
- IgG
-
-
-
-
Application Notes
- IF(IHC-P) 1:50-200
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- 1 μg/μL
-
Buffer
- Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.
-
Preservative
- ProClin
-
Precaution of Use
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
-
Storage
- -20 °C
-
Storage Comment
- Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
-
Expiry Date
- 12 months
-
-
- VGLL3 (Vestigial Like 3 (VGLL3))
-
Alternative Name
- VGLL3
-
Background
-
Synonyms: Colon carcinoma related protein, Vestigial like 3 Drosophila, VGL 3, VGL-3, VGL3, VGLL3_HUMAN.
Background: The transcriptional enhancer factor-1 (TEF-1) family of transcription factors regulate tissue-specific gene expression in muscle and placenta. The mechanism whereby TEF-1 confers tissue specificity depends largely on the interaction of TEF-1 with tissue-specific cofactors. Transcription cofactor Vgl-3 (vestigial-like protein 3), also known as colon carcinoma related protein, is a 326 amino acid nuclear protein that may act as a specific coactivator for the mammalian transcription elongation factors. Both Vgl-1 and Vgl-3 are enriched in placenta, whereas Vgl-2 is expressed in differentiating somites and branchial arches during embryogenesis and is skeletal-muscle specific in adult tissues. There are two isoforms of Vgl-3 that are produced as a result of alternative splicing events.
-
Gene ID
- 389136
Target
-